Clinical Trials · NCT06387199
Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide
- Phase
- Phase 2/Phase 3
- Recruitment status
- Recruiting
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Enrollment
- 26
- Start date
- Dec 2024
- Locations
- 1 site, Canada
- Primary endpoint
- Percentage of daytime plasma glucose levels spent in target range (semaglutide vs. placebo)